Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2018 Nov 29;175(6):1665-1678.e18.
doi: 10.1016/j.cell.2018.09.038. Epub 2018 Oct 18.

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

Affiliations
Free article

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

Huimin Hu et al. Cell. .
Free article

Abstract

Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with limited therapeutic option and poorly understood mechanism. By studying the mutational landscape of 188 sGBMs, we find significant enrichment of TP53 mutations, somatic hypermutation, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, and MET amplification. Strikingly, METex14 frequently co-occurs with ZM fusion and is present in ∼14% of cases with significantly worse prognosis. Subsequent studies show that METex14 promotes glioma progression by prolonging MET activity. Furthermore, we describe a MET kinase inhibitor, PLB-1001, that demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells in preclinical models. Importantly, this compound also shows blood-brain barrier permeability and is subsequently applied in a phase I clinical trial that enrolls MET-altered chemo-resistant glioma patients. Encouragingly, PLB-1001 achieves partial response in at least two advanced sGBM patients with rarely significant side effects, underscoring the clinical potential for precisely treating gliomas using this therapy.

Trial registration: ClinicalTrials.gov NCT02978261.

Keywords: MET tyrosine-kinase inhibitor; PLB-1001; cancer genomics; clinical trial; data science; precision neuro-oncology; secondary glioblastomas.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback